Navigation Links
CureLauncher is Described on LIVESTRONG Blog as Modern Platform That Gets People Involved in Advancing New Cancer Treatments
Date:12/12/2012

from esteemed cancer researcher Dr. Lee Roy Morgan. People can find information about this experimental treatment at cureLauncher and make a donation to advance the treatment. Ninety one percent of the donations go directly to advancing the new drug. Each person who donates $25 or more can email Dr. Morgan directly and receive his confidential reply.

CureLauncher’s Vice President, David Fuehrer, spoke with Naveen. "My connection to the LIVESTRONG Foundation is both professional and very personal. “At 25, I was a natural bodybuilding champion in New York. Four months later, I was diagnosed with testicular cancer”, said David.

“Lance Armstrong’s book helped me cope with my transition from competitive athlete to cancer patient. Five years later, I was diagnosed with testicular cancer a second time. Throughout the past 10 years, the LIVESTRONG Foundation has helped me accept myself and take action. That inspiration is a big part of why I work with cureLauncher to fund new cancer treatments to save lives”.

To learn more about breast cancer clinical trials or make a donation to the new breast cancer treatment, visit http://www.curelauncher.com
About CureLauncher
CureLauncher is an online platform that advances new cancer treatments. It connects patients to cures and cancer researchers to funding. CureLauncher brings leading cancer researchers and donors together to fund new cures.

Read the full story at http://www.prweb.com/releases/cureLauncher/LIVESTRONG_BLOG/prweb10230062.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. CureLauncher is a New Website That Connects Patients to Trials Across the U.S.
2. Only 16% of Donations go to New Cancer Treatments in Some Charities. With cureLauncher, 91% of Contributions Go Directly to New Cures for Cancer.
3. Nano-FTIR - A new era in modern analytical chemistry
4. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
5. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
6. Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform
7. Automated Online Sample Preparation Comes to Waters UltraPerformance Liquid Chromatography (UPLC) Platform
8. New Crowdfunding Platform, ScitechStarter, Focuses on Science and Technology Innovators
9. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
10. New England Cord Blood Bank chooses Sepax 2 from Biosafe as their Cord Blood Processing Platform
11. New Report: "Innovations in Drug Delivery - Broad-based Proprietary Technology Platforms to Address Delivery Efficiency and Improve Patient Compliance" Now Available at Twease.org
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ...  Case No. 3:13-cv-03494-M and  Spherix v. Uniden Corporation ... the United States District Court for the Northern ... On November 21, 2014 the Markman ...
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
(Date:11/22/2014)... (PRWEB) November 21, 2014 On November ... at the 2014 Emerging Medical Technologies Summit in San ... Awards. Widely regarded among Silicon Valley investors and ... device innovation, the win also positions Briteseed to ... Innovator competition in 2015 and compete with other elite ...
(Date:11/22/2014)... , November 21, 2014 ... wechselt als Chief Commercial Officer zu KLOX    ... der Unternehmensentwicklung und Chief Financial Officer bestellt    ... mit der Vermarktung seines jüngst zugelassenen Behandlungssystems zur Wundheilung ... ("KLOX" bzw. das "Unternehmen") ist sehr erfreut, die folgenden ...
Breaking Biology Technology:Markman Hearing Held as Scheduled in VTech and Uniden Cases 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5
... MA - In work that could jumpstart the promising field ... body to treat a variety of diseases and tissue defects, ... that could solve one of the key challenges associated with ... transplantation. In the work, reported in the journal ...
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced ... has published results from the North American Phase 3 trial ... fidaxomicin as a treatment for patients with Clostridium difficile ... significantly reduced recurrence rates and increased global cure rates when ...
... ST. LOUIS, Feb. 2, 2011 Sigma Life Science, the ... SIAL ), today announced that its SAGE Labs initiative ... genomes for six of the most widely used strains of ... generate and analyze sequence data using next generation sequencing systems, ...
Cached Biology Technology:Engineered cells could usher in programmable cell therapies 2Engineered cells could usher in programmable cell therapies 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 2The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 3The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 4The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 5The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI) 6Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 2Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 3Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database 4
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
(Date:11/7/2014)... 6, 2014 Leading Biometric companies aim ... security revolutionizing online transactions.  Companies in focus today are: NXT-ID, ... BABA ), Google Inc. (NASDAQ: GOOG ... (NASDAQ: EBAY ) and MasterCard Inc. (NYSE: MA) ... NXTDW), a biometric authentication company focused on the growing mobile ...
(Date:11/6/2014)... of metastasis, yet progress in preventing and treating ... been particularly challenging to design drugs that work ... systems biology at Harvard Medical School. , ... already metastasized." , Gujral and colleagues have now ... better understand how metastasis begins. Their findings may ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3
... A tiny, fast switch that uses water droplets to create ... mechanism found in palm beetles. , The new beetle-inspired ... on the scale of a micron -- a millionth of ... larger applications like powerful adhesive bonding. Like the transistor, whose ...
... that the brains of alcoholics are smaller, lighter ... speakers at the October 2004 Congress for the ... Mannheim, Germany reviewed what is known about the ... shrinkage. Proceedings are published in the June issue ...
... and Infectious Diseases (NIAID), part of the National Institutes ... which cause such serious diseases as West Nile fever, ... defenses in different ways depending on whether they are ... to new approaches to developing vaccines and treatments against ...
Cached Biology News:Beetle-inspired switch uses water for bonding 2Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
DNA fragmentation factor & Inhibitor of CAD...
Component in MasterPure™ Purification Kits...
Anti-gp340 Monoclonal Antibody Description: 100 g Research Focus: cancer & cell proliferation Storage: -20C Shipping Temperature: 4C...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Biology Products: